At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BLRX BioLine Rx
Post-Mkt 08-27 18:04:54 EDT
2.76
+0.06
+2.22%
盘后2.71
-0.05-1.80%
17:50 EDT
High2.85
Low2.76
Vol2.27K
Open2.85
D1 Closing2.70
Amplitude3.33%
Mkt Cap12.01M
Tradable Cap11.52M
Total Shares4.35M
T/O6.37K
T/O Rate0.05%
Tradable Shares4.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.